Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Receivables (2020 - 2023)

Immuneering's Receivables history spans 4 years, with the latest figure at $1046.0 for Q1 2023.

  • On a quarterly basis, Receivables fell 99.63% to $1046.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $1046.0, a 99.63% decrease, with the full-year FY2022 number at $12417.0, down 94.95% from a year prior.
  • Receivables came in at $1046.0 for Q1 2023, down from $12417.0 in the prior quarter.
  • The five-year high for Receivables was $500110.0 in Q4 2020, with the low at $1046.0 in Q1 2023.
  • Historically, Receivables has averaged $250479.1 across 4 years, with a median of $246040.0 in 2021.
  • Biggest five-year swings in Receivables: plummeted 50.8% in 2021 and later plummeted 99.63% in 2023.
  • Year by year, Receivables stood at $500110.0 in 2020, then crashed by 50.8% to $246040.0 in 2021, then tumbled by 94.95% to $12417.0 in 2022, then tumbled by 91.58% to $1046.0 in 2023.
  • Business Quant data shows Receivables for IMRX at $1046.0 in Q1 2023, $12417.0 in Q4 2022, and $70180.0 in Q3 2022.